These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18484799)

  • 41. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion.
    Cryan JF; Gasparini F; van Heeke G; Markou A
    Drug Discov Today; 2003 Nov; 8(22):1025-34. PubMed ID: 14690633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Shiffman S
    Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats.
    Yuan M; Malagon AM; Yasuda D; Belluzzi JD; Leslie FM; Zaveri NT
    Behav Brain Res; 2017 Aug; 333():251-257. PubMed ID: 28693859
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New trends in the treatment of nicotine addiction.
    Sliwińska-Mossoń M; Zieleń I; Milnerowicz H
    Acta Pol Pharm; 2014; 71(4):525-30. PubMed ID: 25272878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacotherapy for Substance Use Disorders.
    Klein JW
    Med Clin North Am; 2016 Jul; 100(4):891-910. PubMed ID: 27235620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
    Jackson KJ; Jackson A; Carroll FI; Damaj MI
    Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
    Bagdas D; Alkhlaif Y; Jackson A; Carroll FI; Ditre JW; Damaj MI
    Neuropharmacology; 2018 Aug; 138():72-79. PubMed ID: 29860196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
    Fagerström K; Balfour DJ
    Expert Opin Investig Drugs; 2006 Feb; 15(2):107-16. PubMed ID: 16433591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Managing nicotine addiction.
    Kotlyar M; Hatsukami DK
    J Dent Educ; 2002 Sep; 66(9):1061-73. PubMed ID: 12374267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats.
    Yamada H; Bishnoi M; Keijzers KF; van Tuijl IA; Small E; Shah HP; Bauzo RM; Kobeissy FH; Sabarinath SN; Derendorf H; Bruijnzeel AW
    Pharmacol Biochem Behav; 2010 Jun; 95(4):401-9. PubMed ID: 20211642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CB
    Saravia R; Flores Á; Plaza-Zabala A; Busquets-Garcia A; Pastor A; de la Torre R; Di Marzo V; Marsicano G; Ozaita A; Maldonado R; Berrendero F
    Biol Psychiatry; 2017 Apr; 81(7):625-634. PubMed ID: 27737762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms.
    Rose JE; Behm FM; Ramsey C; Ritchie JC
    Nicotine Tob Res; 2001 Nov; 3(4):383-90. PubMed ID: 11694206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroscience of nicotine for addiction medicine: novel targets for smoking cessation medications.
    D'Souza MS
    Prog Brain Res; 2016; 223():191-214. PubMed ID: 26806777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blockade of nicotinic acetylcholine or dopamine D1-like receptors in the central nucleus of the amygdala or the bed nucleus of the stria terminalis does not precipitate nicotine withdrawal in nicotine-dependent rats.
    Jonkman S; Markou A
    Neurosci Lett; 2006 May; 400(1-2):140-5. PubMed ID: 16563623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice.
    Hamouda AK; Jackson A; Bagdas D; Imad Damaj M
    Nicotine Tob Res; 2018 Jun; 20(7):903-907. PubMed ID: 29059422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treating tobacco addiction--nicotine or no nicotine?
    Benowitz NL
    N Engl J Med; 1997 Oct; 337(17):1230-1. PubMed ID: 9337385
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy?
    Sims TH; Fiore MC
    CNS Drugs; 2002; 16(10):653-62. PubMed ID: 12269859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Critical Review of Repurposing Apomorphine for Smoking Cessation.
    Morales-Rosado JA; Cousin MA; Ebbert JO; Klee EW
    Assay Drug Dev Technol; 2015 Dec; 13(10):612-22. PubMed ID: 26690764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.
    Harmey D; Griffin PR; Kenny PJ
    Nicotine Tob Res; 2012 Nov; 14(11):1300-18. PubMed ID: 23024249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacotherapy for smoking cessation.
    Nunn-Thompson CL; Simon PA
    Clin Pharm; 1989 Oct; 8(10):710-20. PubMed ID: 2680239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.